ShipraGandhiMD

Oncology • Buffalo, NY

Physician

Join to view full profile

Dr. Gandhi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gandhi's full profile

Already have an account?

Office
Elm and Carlton Streets RPCI Clinical Practice Plan
Buffalo, NY 14263
Phone+1 716-845-2300

Fax+1 716-898-3279

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 2015 - 2018
University at BuffaloResidency, Internal Medicine, 2012 - 2015
Lady Hardinge Medical CollegeClass of 2011

Certifications & Licensure

NY State Medical License 2015 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer Start of enrollment: 2019 Jan 09
Completed
Early Phase 1
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer Start of enrollment: 2019 Dec 06
Completed
Phase 1
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer Start of enrollment: 2022 Dec 19
Recruiting
Phase 2
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2018 Jan 31
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Start of enrollment: 2023 Aug 22
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Breast Cancer Start of enrollment: 2023 Oct 16
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer Start of enrollment: 2024 Feb 16
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer Start of enrollment: 2024 Oct 01
Not yet recruiting
Phase 2
Roles: Principal Investigator, Contact
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer Start of enrollment: 2024 Aug 30
Not yet recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Detrimental Impact of Chemotherapy Dose Reduction or Discontinuation in Early Stage Triple-Negative Breast Cancer Treated With Pembrolizumab and Neoadjuvant Chemothera...
Jayasree Krishnan, Archit Patel, Arya Mariam Roy, Malak Alharbi, Ankita Kapoor
Clinical Breast Cancer. 2024-12-01
Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Shipra Gandhi, Ronald T Slomba, Cayla Janes, Victoria Fitzpatrick, Janine Miller
Journal for Immunotherapy of Cancer. 2024-11-14
Dendritic Cell Plasticity, Radiation, and Newton's Third Law.
Pawel Kalinski, Shipra Gandhi, Kathleen M Kokolus
Clinical Cancer Research. 2024-10-01

Press Mentions

Roswell Experts Offer Lifestyle Guidance for Breast Cancer SurvivorsDecember 11th, 2024
AIM ImmunoTech Announces Data Pubished on Part 1 Study on AmpligenNovember 19th, 2024
Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type of Breast CancerNovember 18th, 2024
Join now to see all

ShipraGandhiMD

Dr. Gandhi is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.